GLYCO-IMMUNE CHECKPOINT INHIBITORS
Targeting Glycan-Sensing Checkpoints to Unleash Both the Innate and Adaptive Immune Responses to Cancer

GLYCO-IMMUNE CHECKPOINT INHIBITORS

Immuno-Oncology Today:
An Unmet Need

Despite the early success of first-generation immuno-oncology drugs, most cancer patients do not respond to these treatments or eventually develop resistance.

Learn more

Our Science

Cell surface glycosylation is now known to play a central role in tumor immune evasion: Tumor cells evolve to express distinct immunosuppressive glycan patterns on their surfaces that down-regulate a wide spectrum of innate and adaptive immune cell types, which are critical for a coordinated anti-tumor immune response.

Learn more

The Approach

Palleon Pharmaceuticals is the leading biotechnology company developing drugs to treat cancer by targeting glyco-immune checkpoints, which are glycan-sensing inhibitory receptors found on innate and adaptive immune cells.

Learn more

Twitter

@Palleon_Pharma
Are you looking to get hands-on experience in the design, delivery and management of preclinical in vivo studies of… http://2mRKjyyRQy

@Palleon_Pharma
.@CarolynBertozzi is delivering a keynote @fredhutch's SF Cancer Summit on targeting glycan sensing checkpoints. We… http://ofsVttqGyZ

Visit us on Twitter

Our Founding Science

Hear from Dr. Carolyn Bertozzi on glycoscience, Glyco-Immune Checkpoints, and how Palleon is positioned to advance this unexplored area of immuno-oncology to benefit patients.

Learn more